Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$17.75 - $41.6 $747,310 - $1.75 Million
-42,102 Reduced 18.0%
191,779 $7.6 Million
Q4 2023

Feb 07, 2024

BUY
$8.54 - $20.22 $568,533 - $1.35 Million
66,573 Added 39.79%
233,881 $4.46 Million
Q3 2023

Nov 09, 2023

BUY
$10.13 - $13.98 $261,445 - $360,809
25,809 Added 18.24%
167,308 $1.92 Million
Q2 2023

Aug 09, 2023

BUY
$6.84 - $11.91 $12,496 - $21,759
1,827 Added 1.31%
141,499 $1.45 Million
Q1 2023

May 12, 2023

BUY
$7.0 - $8.75 $286,055 - $357,568
40,865 Added 41.36%
139,672 $1.08 Million
Q4 2022

Feb 09, 2023

BUY
$5.45 - $7.35 $258,531 - $348,661
47,437 Added 92.34%
98,807 $726,000
Q2 2022

Aug 12, 2022

SELL
$6.71 - $9.52 $11,366 - $16,126
-1,694 Reduced 3.19%
51,370 $437,000
Q4 2021

Feb 09, 2022

BUY
$10.41 - $13.95 $28,107 - $37,665
2,700 Added 5.36%
53,064 $735,000
Q3 2021

Nov 12, 2021

BUY
$8.19 - $11.31 $41,474 - $57,273
5,064 Added 11.18%
50,364 $538,000
Q1 2021

May 14, 2021

SELL
$10.02 - $13.92 $28,597 - $39,727
-2,854 Reduced 5.93%
45,300 $480,000
Q4 2020

Feb 25, 2021

BUY
$7.42 - $15.96 $357,302 - $768,537
48,154 New
48,154 $607,000

Others Institutions Holding ALPN

About ALPINE IMMUNE SCIENCES, INC.


  • Ticker ALPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,006,700
  • Description
  • Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...
More about ALPN
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.